Is major depression associated with serum levels of tumor necrosis factor-alpha in patients with rheumatoid arthritis?

Uğuz, Faruk; Küçük, Adem; Aydogan, Semra; Arslan, Şevket; Kurt, Hatıce Guncu; Toker, Aysun; Şahin, Muhammed

doi:10.1016/j.jpsychores.2015.09.011

Cited by 8 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of anxiety across the 47 studies ranged from 2.4% to 77%, noting that two studies reported significantly higher prevalence rates (70%, 77%) 13,52 compared with the other studies at the upper prevalence range. Prevalence based on studies using clinical diagnosis of anxiety disorders ranged from 5 to 70% 16,17,52–54,56–58 . Specifically, prevalence rates for GAD using the DSM‐IV 5%–13.4% or the Structured Clinical Interview for DSM Disorders (SCID) (5% – 16.9%) 17,54,57 were lower than the rates reported for “any anxiety disorder” (13.4%– 22.9% SCID) 54,56–58 and 70% on International Classification of Diseases, Tenth Revision 52 .…”

Section: Resultsmentioning

confidence: 98%

“…Overall, six studies 15,17,23,30,36,37 provided sufficient data on anxiety and adjusted for confounding variables that may influence anxiety in patients with RA. Most studies reported on examining at least one association (demographic, clinical, psychological or other) with anxiety, except five studies 32,42,44,48,58 . Ten studies 14,18,19,27,29,32,35,36,44,54 did not include consideration of the implications of comorbidity of anxiety and RA on either condition.…”

Section: Resultsmentioning

confidence: 99%

“…The other studies included multiple thresholds (DASS42, 21,22 ; DASS21, 42 ; PROMIS, 23,54 ) or single (Cattell 28 ) thresholds for case definition. In eight studies, anxiety was determined using diagnostic interviews 16,17,52–54,56–58 . Of those, five studies reported on criteria being met for GAD 16,17,53,54,57 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence, Severity, and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review

Meade,

Joyce,

Perich

et al. 2024

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectivesMany studies have reported high rates of anxiety in adults with Rheumatoid Arthritis (RA). The aim of this systematic review was to examine those findings and determine the overall prevalence, severity, and commonly used measures of anxiety in individuals with RA.MethodsSix databases were searched from January 2000 without restrictions on language/location, study design, or grey literature. All identified studies that examined anxiety prevalence and severity in adults with RA, as assessed with clinical diagnostic interview and/or standardised self‐report measures, were considered for inclusion. Quality assessment of included studies was conducted using a modified Newcastle‐Ottawa Evaluation Scale, and the findings were synthesised via a narrative approach.ResultsAcross the 47 studies (n =11,085) the sample size ranged from 60 to 1321 with seven studies including healthy controls or groups with other health conditions. The studies were conducted across 23 countries and anxiety prevalence ranged from 2.4% to 77% predominantly determined with standardised self‐report measures, of which Hospital Anxiety and Depression scale was used most frequently; only eight studies used a clinical diagnostic interview to confirm a specific anxiety diagnosis. Notable associations with anxiety in RA were physical disability, pain, disease activity, depression, and quality of life.ConclusionsThe reported prevalence of anxiety in RA varied widely potentially due to use of different self‐report measures and cut‐off points. Such cut‐off points will need to be standardised to clinical thresholds to inform appropriate interventions for anxiety comorbidity in RA.This article is protected by copyright. All rights reserved.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence, Severity, and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review

Meade,

Joyce,

Perich

et al. 2024

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Many researchers reported the altered levels of certain biological markers both proinflammatory cytokines and chemokines may be responsible for MDD (Cassano et al, 2017; Lopresti et al, 2013; Schmidt et al, 2011). Some study observed the elevated serum levels of IL-1β, TNF-α, cortisol, CRP, IL-6, IL-10, IL-15, IL-18, and MDA in MDD patients while others showed no alterations (Fan et al, 2017; Islam et al, 2018; Nishuty et al, 2019; Oglodek et al, 2017; Rivera et al, 2014; Uguz et al, 2015; Yang et al, 2007). Some studies demonstrated positive correlations between these markers and severity of depression (Dahl et al, 2014; Dowlati et al, 2010; Farooq et al, 2017; Grassi-Oliveira et al, 2011; Haapakoski et al, 2015) whereas others reported a negative association between them (Einvik et al, 2012; Rief et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder

Das

Emon

Shahriar

et al. 2020

Preprint

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a serious psychiatric disorder but there are no reliable risk assessment tools for this condition. The actual reason for affecting depression is still controversial. It is assumed that the dysregulated cytokines are produced due to the hyperactivation of the immune system in depression. We aimed to evaluate the possible alteration and the role of serum interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in MDD patients. The diagnostic and statistical manual of mental disorders, 5th edition was used to diagnose patients and evaluation of healthy controls (HCs). The severity of depression was measured by the Hamilton depression rating scale (Ham-D). Serum IL-1β and TNF-α levels were quantified by enzyme-linked immunosorbent assay kits. Increased levels of serum IL-1β and TNF-α were observed in MDD patients compared to HCs. These higher levels of peripheral markers were positively correlated with the severity of depression. Moreover, females with higher Ham-D scores showed greater serum IL-1β and TNF-α levels compared to males. Good predictive values were detected for both serum IL-1β and TNF-α levels by receiver operating characteristic analysis. Therefore, the elevated levels of serum IL-1β and TNF-α might be used as risk assessment indicators for MDD.

show abstract

“…Имеются убедительные доказательства того, что депрессия оказывает негативное влияние на течение РА. Уровень депрессии положительно коррелирует с активностью заболевания, депрессия может способствовать усилению болевого синдрома в суставах, снижению эффективности лечения и ухудшению качества жизни, связанного со здоровьем[1,21]. Депрессия в значительной степени связана с функциональными ограничениями, побочными эффектами лекарств, а также неуверенностью пациентов в отношении прогноза заболевания и вероятности инвалидизации[16].…”

unclassified

Cytokines and Depression in Patients With Rheumatoid Arthritis

Grekhov¹,

Alexandrov²,

Krasilnikov³

et al. 2022

СПНО (MPSE)

View full text Add to dashboard Cite

В обзорной статье рассматривается роль семейства цитокинов в патогенезе ревматоидного артрита (РА), обсуждаются механизмы функционирования системы цитокинов, в частности фактора некроза опухоли (TNF) и интерлейкина (IL-6), которые играют центральную роль в патогенезе РА, выяснение которых привело к разработке новых терапевтических средств, таких как DMARDs и ингибиторы JAK, которые показали хороший эффект при клинических испытаниях. Основное внимание в работе уделено сопутствующему депрессивному состоянию пациентов с РА, которое пагубно влияет на исходы заболевания (активность, осложнения, уровень боли, вероятность ремиссии, качество жизни и смертность). Эти два заболевания могут усугублять друг друга с помощью пока не известных механизмов, однако приводятся данные, подтверждающие тесную связь депрессии с системным воспалением, особенно с нарушением регуляции цитокиновой системы. Этот обзор был сосредоточен на воспалительных цитокинах и сигнальных путях, которые могут служить потенциальными медиаторами между РА и депрессией. Одной из целей обзора было определение потенциальных общих терапевтических мишеней как для лечения РА, так и для лечения депрессии. Сделан вывод о том, что лечение больных РА биологическими препаратами, которые очень эффективно подавляют провоспалительные цитокины, может уменьшить обострение и распространенность симптомов депрессии у пациентов с РА. Ключевые слова: ревматоидный артрит, цитокины, депрессия, патогенез, терапия.

show abstract

Is major depression associated with serum levels of tumor necrosis factor-alpha in patients with rheumatoid arthritis?

Cited by 8 publications

References 32 publications

Prevalence, Severity, and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review

Prevalence, Severity, and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review

Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder

Cytokines and Depression in Patients With Rheumatoid Arthritis

Contact Info

Product

Resources

About